Correlation Between Krystal Biotech and Blueprint Medicines

Can any of the company-specific risk be diversified away by investing in both Krystal Biotech and Blueprint Medicines at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Krystal Biotech and Blueprint Medicines into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Krystal Biotech and Blueprint Medicines Corp, you can compare the effects of market volatilities on Krystal Biotech and Blueprint Medicines and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Krystal Biotech with a short position of Blueprint Medicines. Check out your portfolio center. Please also check ongoing floating volatility patterns of Krystal Biotech and Blueprint Medicines.

Diversification Opportunities for Krystal Biotech and Blueprint Medicines

0.36

Correlation Coefficient

Krystal Biotech  Blueprint Medicines

Weak diversification

The 3 months correlation between Krystal and Blueprint is 0.36. Overlapping area represents the amount of risk that can be diversified away by holding Krystal Biotech and Blueprint Medicines Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Blueprint Medicines Corp and Krystal Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Krystal Biotech are associated (or correlated) with Blueprint Medicines. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Blueprint Medicines Corp has no effect on the direction of Krystal Biotech i.e., Krystal Biotech and Blueprint Medicines go up and down completely randomly.

Pair Corralation between Krystal Biotech and Blueprint Medicines

Given the investment horizon of 90 days Krystal Biotech is expected to generate 0.94 times more return on investment than Blueprint Medicines. However, Krystal Biotech is 1.07 times less risky than Blueprint Medicines. It trades about 0.05 of its potential returns per unit of risk. Blueprint Medicines Corp is currently generating about 0.03 per unit of risk. If you would invest  18,678  in Krystal Biotech on August 31, 2024 and sell it today you would earn a total of  1,013  from holding Krystal Biotech or generate 5.42% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Krystal Biotech  vs.  Blueprint Medicines Corp

Krystal Biotech

Risk-Adjusted Performance

3 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Krystal Biotech are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Krystal Biotech may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Blueprint Medicines Corp

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Blueprint Medicines Corp are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound primary indicators, Blueprint Medicines is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.

Pair Trading with Krystal Biotech and Blueprint Medicines

The main advantage of trading using opposite Krystal Biotech and Blueprint Medicines positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Krystal Biotech position performs unexpectedly, Blueprint Medicines can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will offset losses from the drop in Blueprint Medicines' long position.

The idea behind Krystal Biotech and Blueprint Medicines Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.